Zydus Lifesciences shares surged 2% on March 28’s early trading session, despite the company receiving four observations from the United States Food and Drug Administration (USFDA).
At 9:31 am, Zydus Lifesciences was trading at Rs 1,005, up Rs 5.40, or 0.54 percent, on the BSE.
USFDA conducted an inspection at the firm’s Onco Injectable manufacturing plant in Ahmedabad from March 18 to 27. The inspection concluded with four observations, and there were no data integrity-related issues, the company stated.
Zydus Lifesciences stated that it would collaborate closely with the USFDA to address the observations.
As of 1:21 pm, the shares were trading 2.03% higher at ₹1,020.00.
